This first-of-its-kind study of IL-15 in an established neuroblastoma PDX model provided compelling preclinical data that IL-15 should be evaluated in future clinical studies, at least to compare its tolerability against that of IL-2 in paediatric patients. The gene discussed is IL15; the disease is neuroblastoma.